Anavex Life Sciences (AVXL) Cash & Current Investments (2010 - 2025)

Anavex Life Sciences' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $131.7 million for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 9.09% year-over-year to $131.7 million; the TTM figure through Dec 2025 stood at $131.7 million (up 9.09% YoY), while the FY2025 annual figure was $102.6 million, down 22.4% from the prior year.
• Cash & Current Investments came in at $131.7 million for Q4 2025 at Anavex Life Sciences, up from $102.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $157.6 million in Q2 2021 to a low of $75.9 million in Q1 2021.
• A 5-year average of $136.1 million and a median of $143.7 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments surged 470.47% in 2021 and retreated 27.09% in 2025, its largest moves.
• Anavex Life Sciences' Cash & Current Investments stood at $151.1 million in 2021, then fell by 4.98% to $143.6 million in 2022, then climbed by 0.1% to $143.8 million in 2023, then slipped by 15.99% to $120.8 million in 2024, then increased by 9.09% to $131.7 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $131.7 million, $102.6 million, and $101.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison